Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Systemic Lupus Erythematosus
NCT02349061Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Ustekinumab with Placebo -> Ustekinumab (2 arms). Primary endpoint: Systemic Lupus Erythematosus Responder Index 4 Composite Response at 24 weeks. Started Oct 2015; status: completed.
02
Drugs
ustekinumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02349061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349061.